Revolade 50mg tablets |Eltrombopag | MHP

About This Presentation
Title:

Revolade 50mg tablets |Eltrombopag | MHP

Description:

Revolade 50mg is the indicated for the treatment of patients having Severe aplastic Anemia.Buy Revolade 50mg tablets @ MHP – PowerPoint PPT presentation

Number of Views:8

less

Transcript and Presenter's Notes

Title: Revolade 50mg tablets |Eltrombopag | MHP


1
Revolade 50mg tablets Eltrombopag MHP
2
DESCRIPTION
  • Eltrombopag is sold under the brand name Revolade
    50 mg and it is a man-made form of a protein that
    increases production of platelets (blood-clotting
    cells) in your body. 

3
(No Transcript)
4
DESCRIPTION
  • Revolade 50mg can reduces the risk of bleeding by
    increasing platelets in your blood.Revolade 50mg
    tablet which is used asprescription drug under
    the guidance of the medical practioners

5
INDICATION
  • Revolade 50mg is an anticancer medication which
    isIndicated for the treatment of patients
    having Severe aplastic Anemia First line
    treatment of severe aplastic Anemia Treatment
    of refractory severe aplastic Anemia

6
(No Transcript)
7
  • Indicated for the treatment to stimulate the
    growth and development of platelets in the bone
    marrowPrimarily indicated for the treatment of
    patients having reduced platelet counts due to
    chronic hepatitis C virus infection

8
MECHANISM OF ACTION
  • Eltrombopag consist of class of drugs known as
    thrombopoietin (TPO) receptor agonists. A class
    of drugs is a group of medications which work in
    a same way.Eltrombopag mechanism by raising
    cells in your bone marrow and causes these cells
    to make more platelets. This effect reduces your
    risk of bleeding.

9
PROPERTIES
10
PROPERTIES
  • Ingredients  Eltrombopag 
  • Strength  50mg
  • Package  7 tablets in a strip

11
ADME
  • AbsorptionHigh plasma concentration is 2-6
    hours
  • DistributionMaximum human plasma protein
    bounding is gt99 and in blood plasma level is 50
    to 79

12
ADME
  • Metabolismgenerally metabolised via cleavage,
    oxidation and conjugation with glucuronic acid.
  • EliminationRevolade 50mg eliminated mainly via
    feces 59, along with 31 via renally
    excretedRevolade 50mg Half-life for healthy
    patients is 21-23 hours and idiopathic
    thrombocytopenic purpura is 26-35 hours

13
DOSAGE MANAGEMENT
  • The usual dose for Chronic Hepatitis C-associated
    Thrombocytopenia is 25 mg PO qDay. Dose is
    managed in 25 mg accretion q2weeks PRN to attain
    target Plt needed to start/control antiviral
    therapy with pegylated interferon and ribavirin
    not to exceed 100 mg/day 

14
(No Transcript)
15
Severe Aplastic Anemia
  • First-line therapy When combination with
    standard immunosuppressive treatment, for
    patients with serious aplastic Anemia (SAA) The
    usual dose for severe Aplastic Anemia 150 mg PO
    qDay for 6 months Avoid taking of more than
    starting dose total duration is 6 months 

16
  • Refractory SAA In this condition the drug given
    who fail to respond enough to at least 1 before
    immunosuppressive therapy The usual dose for
    Refractory SAA 50 mg PO qDay The recommended
    dose for Chronic Immune Thrombocytopenia is 50 mg
    PO qDay Adjust dose to manage and control
    platelet count (Plt) gt50 x 109/L to reduce the
    risk of bleeding not to exceed 75 mg/day

17
PRECAUTIONS
  • The drug Revolade 50mg may have high risk of
    severe and probably life-threatening
    hepatotoxicity monitor liver function before and
    during treatment
  • While receiving the drug, if patient with hepatic
    impairment (Child-Pugh Class A, B, C) initiates
    therapy for first- line treatment of severe
    aplastic Anemia, reduce initial dose

18
(No Transcript)
19
PRECAUTIONS
  • When treatment, If the patients have cataracts,
    do not use the drug due to the Revolade
    50mg effects cataracts and make the condition
    worse.
  • Avoid the Revolade 50mg while the patients have
    myelodysplastic syndrome (MDS), will increases
    the risk of death.

20
PRECAUTIONS
  • While on treatment with drug Revolade then Portal
    vein thrombosis reported in patients with chronic
    liver disease.

21
SIDE EFFECTS
  • Common side effects of Revolade 50mg 
    Headache Cough Loss of appetite Flu
    Reduced red blood cells Diarrhoea Nausea
    Fever Weakness

22
SIDE EFFECTS
  • Serious side effects of Revolade 50mg 
    Swelling of legs Abdomen swelling Confusion
    Chest pain Dyspnea Cloudy vision Urine in
    dark colour Yellowing of your skin
    Sensitivity to light Seeing circles around
    lights

23
(No Transcript)
24
  • PREGNANCY
  • Pregnancy category is C Safety of drug
    during pregnancy is not established
  • LACTATION
  • During breast feeding, avoid using of
    drug Revolade
  • 50mg
  • STORAGE
  • Store at room temperature 20C and 25C.

25
CONTACT US
  • EMAIL millionhealthpharmaceuticals_at_gmail.
    com
  •  
  • PHONE NO 91-9940472902 
  • WEBSITE  https//millionpharma.com/eltrombopag-
    50mg.php

26
(No Transcript)
Write a Comment
User Comments (0)